Stonebridge Capital Advisors LLC lifted its stake in GlaxoSmithKline plc (NYSE:GSK) by 4.0% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 26,953 shares of the pharmaceutical company’s stock after acquiring an additional 1,027 shares during the quarter. Stonebridge Capital Advisors LLC’s holdings in GlaxoSmithKline were worth $1,126,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. Boston Partners purchased a new position in GlaxoSmithKline in the fourth quarter valued at about $65,234,000. Norges Bank bought a new position in GlaxoSmithKline during the 4th quarter worth approximately $17,275,000. Two Sigma Investments LP bought a new position in GlaxoSmithKline during the 4th quarter worth approximately $15,936,000. Deutsche Bank AG lifted its holdings in GlaxoSmithKline by 221.0% during the 4th quarter. Deutsche Bank AG now owns 529,309 shares of the pharmaceutical company’s stock worth $20,222,000 after buying an additional 364,431 shares during the last quarter. Finally, Millennium Management LLC lifted its holdings in GlaxoSmithKline by 612.0% during the 4th quarter. Millennium Management LLC now owns 365,325 shares of the pharmaceutical company’s stock worth $13,959,000 after buying an additional 314,016 shares during the last quarter. 11.26% of the stock is owned by institutional investors.

Shares of GlaxoSmithKline stock traded down $0.01 on Friday, reaching $40.12. 41,530 shares of the company were exchanged, compared to its average volume of 2,158,889. The company has a current ratio of 0.72, a quick ratio of 0.48 and a debt-to-equity ratio of 6.92. The stock has a market capitalization of $99.17 billion, a price-to-earnings ratio of 12.69, a PEG ratio of 2.09 and a beta of 0.74. GlaxoSmithKline plc has a 1-year low of $36.41 and a 1-year high of $42.36.

GlaxoSmithKline (NYSE:GSK) last announced its quarterly earnings results on Wednesday, May 1st. The pharmaceutical company reported $0.79 earnings per share for the quarter, topping analysts’ consensus estimates of $0.66 by $0.13. The business had revenue of $9.98 billion for the quarter, compared to analysts’ expectations of $9.86 billion. GlaxoSmithKline had a return on equity of 171.27% and a net margin of 12.27%. Sell-side analysts predict that GlaxoSmithKline plc will post 2.91 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, July 11th. Stockholders of record on Friday, May 17th will be given a dividend of $0.4953 per share. This represents a $1.98 dividend on an annualized basis and a dividend yield of 4.94%. The ex-dividend date of this dividend is Thursday, May 16th. GlaxoSmithKline’s payout ratio is 61.71%.

A number of research analysts have commented on GSK shares. UBS Group downgraded GlaxoSmithKline from a “buy” rating to a “neutral” rating in a report on Friday, February 22nd. Shore Capital downgraded GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Friday, March 8th. Zacks Investment Research downgraded GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Thursday, April 25th. Finally, Cowen reaffirmed a “hold” rating and set a $45.00 target price on shares of GlaxoSmithKline in a report on Monday. One analyst has rated the stock with a sell rating, sixteen have given a hold rating and four have assigned a buy rating to the company’s stock. GlaxoSmithKline presently has a consensus rating of “Hold” and an average price target of $42.28.

In related news, Director Plc Glaxosmithkline purchased 385,714 shares of the company’s stock in a transaction dated Tuesday, May 28th. The shares were acquired at an average cost of $14.00 per share, for a total transaction of $5,399,996.00. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. 10.00% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The original version of this piece of content can be viewed at https://www.watchlistnews.com/stonebridge-capital-advisors-llc-has-1-13-million-stake-in-glaxosmithkline-plc-nysegsk/3041571.html.

GlaxoSmithKline Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Featured Story: Analyst Ratings Trading

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.